Polyrizon has completed enrollment of all 120 participants in its U.S. clinical study of NASARIX, the company's nasal-gel allergy blocker, with patients randomized across five clinical sites nationwide. The milestone moves the trial into its data-collection phase and brings the novel non-pharmacological approach to allergy management a step closer to potential commercialization.
NASARIX is based on a bioadhesive gel platform designed to coat nasal passages and act as a physical barrier against airborne allergens — pollen, pet dander, dust mites — before they can bind to mucosal tissue and trigger the IgE-mediated cascade responsible for allergic symptoms. The mechanism is distinct from antihistamines and intranasal corticosteroids in that it requires no systemic absorption; the barrier acts locally and is cleared naturally. That positioning aligns it with the broader functional wellness trend toward non-drug, barrier-based or microbiome-adjacent interventions.
Trial Design
The randomized, controlled study spans five U.S. clinical sites, with all 120 planned participants now enrolled. Full trial design details — including blinding protocol, primary clinical endpoints, and duration — have not been disclosed in the current announcement. Results, when published, will be critical for substantiating any structure-function or drug claims depending on the regulatory pathway Polyrizon pursues with the FDA.
Market Context
Allergy management is a high-volume, high-frequency consumer health category. An estimated 81 million Americans are diagnosed with seasonal allergic rhinitis annually, and the global allergic rhinitis therapeutics market is valued in the multi-billion-dollar range, with significant interest in non-steroidal and non-sedating alternatives. Within the functional health space, nasal and mucosal delivery formats have attracted growing formulation attention — from saline rinses and xylitol sprays to probiotic-based nasal products targeting the upper respiratory microbiome. A clinically validated physical barrier product would compete in this increasingly crowded better-for-you respiratory wellness segment.
For nutraceutical and functional food operators, the NASARIX trial is worth tracking as a bellwether for clinically positioned, non-ingestible wellness formats that increasingly compete for the same consumer health dollar as supplements and fortified foods. Brands building out allergy and immune-support portfolios should note consumer appetite for non-pharmacological options that pair naturally with dietary interventions such as quercetin, butterbur, and omega-3 formulations commonly positioned for histamine and inflammatory response.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
